ArticleAntibiotics (Basel, Switzerland)2025
Evaluation of a Novel Rapid Phenotypic Antimicrobial Susceptibility Testing System.
Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPhenotypic antimicrobial susceptibility testing (AST) is essential for guiding timely and effective antibiotic therapy. Rapid and accurate reporting of AST results enables earlier optimization of treatment and supports antimicrobial stewardship by minimizing unnecessary use of broad-spectrum antibiotics. This study aimed to evaluate the performance of the Selux DX Next-Generation Phenotyping AST system in comparison with the standard-of-care MicroScan WalkAway Plus system and broth microdilution reference results.
methodsA total of 332 clinical isolates and 97 Antimicrobial Resistance (AR) Bank reference isolates were tested using the Selux DX and MicroScan systems. Performance was assessed by categorical agreement (CA), error rates [very major errors (VMEs), major errors (MEs), minor errors (mEs)], and turnaround time.
resultsThe Selux DX system demonstrated ≥90% CA for most drug-organism combinations, consistent with Clinical and Laboratory Standards Institute (CLSI) acceptance thresholds, although elevated error rates were noted for erythromycin, aztreonam, cefazolin, minocycline, and ampicillin/sulbactam. Across 5124 drug-bug combinations, 55 VMEs (1.1%), 42 MEs (0.8%), and 203 mEs (4.0%) were identified. The Selux DX system achieved a markedly shorter average turnaround time of 5.5 h compared with 16 h for the MicroScan system, though at the cost of a longer setup time.
conclusionsThe Selux DX system provides rapid and reliable phenotypic AST results, supporting earlier clinical decision-making and antimicrobial stewardship. However, discrepancies with certain antimicrobial agents, particularly among highly resistant reference isolates, highlight the need for further validation in larger, multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.